Alligator Bioscience continues to post convincing phase II data with cancer immunotherapy mitazalimab in pancreatic cancer. Adding to the positive momentum, the Swedish biotech has announced a financing round of up to 80 million MSEK extending its cash runway to Q1 2025. This is setting the company up in a position  of strength for their ongoing partnering discussions. BioStock reached out to Alligator's CEO Søren Bregenholt for a comment on the company's hot streak.